Breast cancer

#ALS #Antibody drug conjugate (ADC) #Breast cancer #Cancer research #DDW Turning Science into Business Symposium #Gene therapy #Hunter Syndrome #Neurodegenerative disorders #Oncology #The University of Manchester #University of California San Diego

This week in Drug Discovery (24 – 28 November) 

News round-up for 24 – 28 November by Bruno Quinney, Content Team at DDW.  This week in drug discovery, gene therapies are providing solutions for complex conditions, most notably in Hunter syndrome but also in amyotrophic lateral sclerosis. Elsewhere, an antibody-drug conjugate precision therapy could prevent breast cancer. … Read More

#News

Cancer research in laboratory
#Breast cancer #Cancer research #Financing

Zetagen raises $12 million to advance breast cancer treatment 

Biopharmaceutical company Zetagen Therapeutics has raised over $12 million to proceed with first-of-its-kind, intratumoural treatments for metastatic and primary breast cancer.  The company announced the closing of its Series B1 financing round, raising $12.9 million. Proceeds will support the advancement of Zetagen’s lead candidate, ZetaMet (Zeta-BC-003), towards commercialisation, the clinical development of ZetaMast (Zeta-MBC-005), and the completion of preclinical studies and GMP manufacturing of ZetaPrime (Zeta-PBC-007).  The… Read More

#Business & Investment #News

Cancer cells
#Antibody drug conjugate (ADC) #Breast cancer #University of California San Diego

ADC precision therapy could prevent breast cancer, study shows 

New research has identified a precision therapy which could stop breast cancer at the source.  Researchers at the University of California San Diego School of Medicine used an antibody-drug conjugate (ADC) to target a cell-surface protein known as FZD7. FZD7 is present on cells with high tumour-initiating potential in… Read More

#Cancer Research #News

#Breast cancer #Cancer research #Eli Lilly

Abemaciclib results offer hope for breast cancer treatment

Pharmaceutical company Eli Lilly has announced encouraging results from the Phase III trial of its Verzenio (abemaciclib) treatment for breast cancer.   The data shows that two years of adjuvant abemaciclib plus endocrine therapy (ET) reduced the risk of death from breast cancer by 15.8% versus… Read More

#News

#Breast cancer #DDW Highlights podcast #Drug therapy #Gene therapy #Prostate cancer

DDW Highlights: 21 October 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, new research showed drug therapies could prevent hereditary diseases. Elsewhere, there were… Read More

#Podcasts

#Breast cancer #DNA mutations #Drug therapy #Gene therapy #Prostate cancer #sympos

This week in Drug Discovery (13 – 17 October)

News round-up for 13 – 17 October by Bruno Quinney, Content Team at DDW.  This week’s top story comes from new research showing drug therapies could prevent hereditary diseases. Elsewhere, there have been major developments in cancer research and gene therapy could help combat hearing loss. … Read More

#News

Breast cancer cell
#Breast cancer

First patient dosed with breast cancer treatment ABY-271

The first patient has been dosed in a Phase I clinical trial of breast cancer treatment ABY-271. ABY-271 is a radiotherapeutic candidate being assessed as a potential treatment for HER2-positive metastatic breast cancer. The Phase I study evaluating the safety, tolerability and biodistribution of ABY-271 is a first-in-human… Read More

#News

Breast cancer
#Breast cancer #Eli Lilly #FDA #Gene mutation #Oncology

FDA approves Inluriyo in ER+, HER2-, ESR1-mutated breast cancer

The US Food and Drug Administration (FDA) has approved Eli Lilly’s Inluriyo (imlunestrant, 200mg tablets), an oral oestrogen receptor antagonist.  It is approved for the treatment of adults with oestrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer (MBC) whose disease progressed after… Read More

#News #Regulatory #Trending News

Cancer cells
#Breast cancer #European Commission #Oncology #Roche

EC approves Roche’s Itovebi for breast cancer subtype

The European Commission has approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and fulvestrant, for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. It is approved following recurrence on or within 12 months of completing… Read More

#News #Regulatory

Patient using a mammography machine
#AstraZeneca #Breast cancer #Cancer Research UK #Gene mutation #Oncology

New approach shows promise in aggressive breast cancers

A clinical trial for early-stage breast cancer patients with BRCA gene mutations has reported 100% survival after three years.  In a Phase III trial, Cancer Research UK researchers stopped BRCA-linked breast cancers growing or coming back by giving patients olaparib tablets 48 hours after each chemotherapy dose. … Read More

#Cancer Research #News #Trending News

Breast cancer
#ASCO #AstraZeneca #Breast cancer #Oncology #The Institute of Cancer Research

Camizestrant reduces risk of breast cancer progression by 56%

Results of a global study presented at the American Society of Clinical Oncology (ASCO) annual meeting have shown that camizestrant for advanced breast cancer can be used to treat emerging tumours.  The study was funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research,… Read More

#Cancer Research #News #Trending News

Breast cancer
#AstraZeneca #Breast cancer #Cancer research #NHS Scotland #Scottish Medicines Consortium (SMC)

SMC accepts AstraZeneca’s breast cancer treatment

AstraZeneca’s Lynparza (olaparib) has been accepted for use within NHS Scotland by the Scottish Medicines Consortium (SMC) to treat adults with HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations after chemotherapy. Breast cancer prevalence In Scotland, nearly 5,000 people are diagnosed with breast cancer each… Read More

#Cancer Research #News

Medical professional examining mammogram
#Breast cancer #Cancer therapeutics #Drug repurposing #ETH Zurich #Oncology

Digoxin prevents breast cancer metastases in a new study

The active ingredient digoxin, a substance found in foxglove, reduces the number of cells in clusters of breast cancer cells circulating in the blood, new research has found.  These clusters are responsible for the formation of metastases in other organs. The smaller the clusters, the fewer metastases… Read More

#Cancer Research #Editor's Choice #News

#Breast cancer #Cancer research #Clinical trials #Solid tumours

New DDW Highlights episode: 27 January 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In the same week that… Read More

#News

#Antibody drug conjugate (ADC) #Bispecific Antibodies #Breast cancer #Oncology #Solid tumours

This week in drug discovery (20-24 January) 

News round-up for 20-24 January by DDW Senior Digital Content Editor Diana Spencer. In the same week that Phesi revealed that breast cancer is the most studied disease for the fourth year in a row, there have been a number of breakthroughs in the treatment of solid tumours,… Read More

#News

#Breast cancer #Cancer research #Clinical trials #Phesi

Breast cancer tops most-studied diseases, study finds 

Phesi has released the results of its annual global analysis of all clinical trials conducted in 2024, using data from its AI-driven Trial Accelerator platform (Figure 1). The analysis of 67,469 recruiting clinical trials reveals that breast cancer is the world’s most studied disease for the fourth consecutive year… Read More

#Cancer Research #News